Accelerating Biologics Development: mAbxience’s “Gene to Biologics Drug Substance (BDS) in 12 Months” ProgramMiguel Martínez-Cava2024-05-29T11:51:27+02:00May 29, 2024|News|
The Future of Biosimilars: Trends and PredictionsMiguel Martínez-Cava2024-02-26T08:56:52+01:00February 26, 2024|News|
Improving Drug Development: The Strategic Value of CDMO PartnershipsMiguel Martínez-Cava2024-02-12T10:05:10+01:00February 12, 2024|News|